Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
Lexeo Therapeutics expands Friedreich ataxia pipeline with LX2006 gene therapy and Mantle Therapeutics acquisitionMergers & AcquisitionsLexeo Expands Friedreich Ataxia Pipeline With Mantle AcquisitionLexeo Therapeutics is expanding its Friedreich ataxia pipeline through the acquisition of Mantle Therapeutics and three CNS-focused collaborations.23 Sep 2026 · 4 min read
Fact-Checked
Envisagenics SpliceCore AI platform identifies tumor-specific RNA splicing targets for precision oncologyMergers & AcquisitionsEnvisagenics, Boehringer Partner on RNA Splicing Cancer TargetsEnvisagenics and Boehringer Ingelheim have entered a multi-year collaboration to validate tumor-specific RNA splicing targets identified by the AI-powered SpliceCore® platform for potential precision oncology therapies.23 Sep 2026 · 3 min read
Fact-Checked
AbbVie and Iambic collaborate on AI-driven small-molecule drug discovery in oncology, immunology and neuroscienceMergers & AcquisitionsAbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug DiscoveryAbbVie and Iambic have launched a multi-year collaboration to apply Iambic’s AI platform to small-molecule drug discovery across oncology, immunology and neuroscience, targeting candidates with first-in-class and best-in-class…22 Sep 2026 · 3 min read
Fact-Checked
Telix ITM radiopharmaceutical merger and radioisotope manufacturing dealMergers & AcquisitionsTelix to Acquire ITM in $1.65 Billion Radiopharmaceutical DealTelix Pharmaceuticals will acquire ITM Isotope Technologies Munich for $1.65 billion in upfront consideration, with up to $700 million in additional milestones.22 Sep 2026 · 3 min read
Fact-Checked
1ST-104 Type 2 LRRK2 and c-Abl dual inhibitor for Parkinson's diseaseMergers & Acquisitions1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals1ST Biotherapeutics has licensed 1ST-104, an oral Type 2 LRRK2 and c-Abl dual inhibitor for Parkinson’s disease, to SK Biopharmaceuticals in an agreement valued at up to $314.8…18 Sep 2026 · 3 min read
Fact-Checked
Roche and Dualitas bispecific antibody discovery collaboration for immunology and inflammationMergers & AcquisitionsRoche, Dualitas Launch Bispecific Antibody Discovery DealRoche and Dualitas Therapeutics have entered a major bispecific antibody discovery collaboration to screen more than 300,000 novel combinations for immunology and inflammation diseases.18 Sep 2026 · 3 min read
Fact-Checked
Lisata Therapeutics acquisition of Marea Therapeutics and $225 million financing for cardioendocrine drug developmentMergers & AcquisitionsLisata Acquires Marea, Raises $225M for Cardioendocrine Drug DevelopmentLisata Therapeutics has acquired Marea Therapeutics in a stock-for-stock transaction and separately secured $225 million in financing to advance MAR001/005 and MAR002 through key clinical milestones.17 Sep 2026 · 3 min read
Fact-Checked
Novo Nordisk and Anthropic collaboration using artificial intelligence for drug discovery and pharmaceutical R&DMergers & AcquisitionsNovo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug DiscoveryNovo Nordisk and Anthropic are collaborating to apply advanced AI models, including Claude Science, to pharmaceutical R&D, biological reasoning and software development, with initial testing focused on selected…16 Sep 2026 · 3 min read
Fact-Checked
GSK Chimagen trispecific T-cell engager targeting two tumour antigens for multiple myelomaMergers & AcquisitionsGSK to Acquire Chimagen’s Trispecific T-Cell Engager for Multiple MyelomaGSK has agreed to acquire Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma. The programme targets T cells and two tumour-associated antigens and is expected to enter Phase…16 Sep 2026 · 3 min read
Fact-Checked
HUTCHMED HMPL-A830 KRAS-EGFR antibody-targeted therapy conjugateMergers & AcquisitionsHUTCHMED Licenses KRAS-EGFR Therapy to GSK in $1.3 Billion DealHUTCHMED has licensed global rights outside Greater China to HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate, to GSK in a deal worth up to $1.295 billion.3 Sep 2026 · 3 min read
Fact-Checked
DualityBio and Genentech collaborate to develop next-generation ADCs using the DUPAC novel-payload platformMergers & AcquisitionsDualityBio, Genentech Strike ADC Deal Worth More Than $1 Billion in Potential MilestonesDualityBio and Genentech have entered a global ADC collaboration centered on the DUPAC novel-payload platform, targeting resistance to topoisomerase inhibitor-based ADCs.28 Aug 2026 · 3 min read
Fact-Checked
McKesson to acquire Precision Medicine Group for $2.25 billion to expand clinical research and biopharma commercialization servicesMergers & AcquisitionsMcKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Clinical Research and Biopharma ServicesMcKesson will acquire Precision Medicine Group for approximately $2.25 billion, expanding its clinical research, biomarker, laboratory, market access and biopharma commercialization capabilities within its Oncology & Multispecialty business.25 Aug 2026 · 2 min read
Fact-Checked
Page 4 of 18